Citadel Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Citadel Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,200	Closed	-$96.4K	–	15417
2025 Q1	$96.4K	Sell	2,200 -14,100	-87%	-$622K	﹤0.01%	11530
2024 Q4	$701K	Buy	16,300 +6,300	+63%	+$286K	﹤0.01%	7826
2024 Q3	$444K	Sell	10,000 -7,000	-41%	-$300K	﹤0.01%	8513
2024 Q2	$676K	Sell	17,000 -3,700	-18%	-$150K	﹤0.01%	7418
2024 Q1	$893K	Buy	20,700 +7,300	+54%	+$315K	﹤0.01%	7150
2023 Q4	$558K	Sell	13,400 -4,700	-26%	-$178K	﹤0.01%	7863
2023 Q3	$719K	Buy	18,100 +7,900	+77%	+$334K	﹤0.01%	7281
2023 Q2	$418K	Buy	10,200 +9,900	+3,300%	+$409K	﹤0.01%	8328
2023 Q1	$12.3K	Buy	300 +100	+50%	+$4.2K	﹤0.01%	13418
2022 Q4	$8.19K	Buy	+200	New	+$8.33K	﹤0.01%	13761

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Citadel Advisors's XPH Position: Q1 2026 in Review

Citadel Advisors reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 42% in Q1 2026, selling an estimated $1.67M and leaving 40,874 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #5874.

Citadel Advisors first reported a position in XPH in Q1 2014 and has held it in 37 quarters since. The position peaked at $3.97M in Q4 2025. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.

Citadel Advisors held 40,874 shares of State Street SPDR S&P Pharmaceuticals ETF worth $2.21M as of Q1 2026.
Citadel Advisors sold 29,990 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $1.67M.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5874 holding.
Citadel Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2014 and has held it in 37 quarters since.
Citadel Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $3.97M in Q4 2025.
82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.